Correction: Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated With dabigatran or rivaroxaban for nonvalvular atrial fibrillation (JAMA Internal Medicine (2016) DOI: 10.1001/jamainternmed.2016.5954);Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation

JAMA Internal Medicine

Volumn 176, Issue 11, 2016, Pages 1662-1671

  Graham, David J ^a   Reichman, Marsha E ^a   Wernecke, Michael ^b   Hsueh, Ya Hui ^a   Izem, Rima ^a   Southworth, Mary Ross ^a   Wei, Yuqin ^b   Liao, Jiemin ^b   Goulding, Margie R ^a   Mott, Katrina ^a   Chillarige, Yoganand ^b   MaCurdy, Thomas E ^a,b,c   Worrall, Chris ^d   Kelman, Jeffrey A ^d  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Acumen LLC   (United States)

^c STANFORD UNIVERSITY   (United States)

^d Centers for Medicare and Medicaid Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; RIVAROXABAN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY RISK; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOEMBOLISM; TREATMENT OUTCOME; VERY ELDERLY; COMPARATIVE STUDY; KAPLAN MEIER METHOD; MORTALITY; RISK FACTOR; UNITED STATES; VALVULAR HEART DISEASE;

AGED; AGED, 80 AND OVER; ANTITHROMBINS; ATRIAL FIBRILLATION; COHORT STUDIES; DABIGATRAN; FACTOR XA INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; HEART VALVE DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICARE; RETROSPECTIVE STUDIES; RISK FACTORS; RIVAROXABAN; STROKE; TREATMENT OUTCOME; UNITED STATES;

EID: 84996590366     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2016.7319     Document Type: Erratum

References (49)

1. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154(13):1449-1457.
2. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;(3):CD001927.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.
4. ReynoldsMW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: A systematic review and metaanalysis. Chest. 2004;126(6):1938-1945.
5. Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim; 2012. http://www .accessdata.fda.gov/drugsatfda-docs/label/2012/022512s011lbl.pdf. Accessed October 2, 2015.
6. Xarelto [package insert]. Leverkusen, Germany: Janssen; 2011. http://www.xareltohcp.com/shared/product/xarelto/prescribing-information.pdf. Accessed August 26, 2016.
7. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151.
8. Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-891.
9. Lip GYH, Larsen TB, Skjøth F, Rasmussen LH. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012;60(8):738-746.
10. Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012;5 (4):480-486.
11. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285 (18):2370-2375.
12. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ,Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham Heart Study. JAMA. 1994;271(11): 840-844.
13. Centers for Medicare & Medicaid Services. Medicare program-general information. https://www.cms.hhs.gov/MedicareGenInfo/. Accessed June 26, 2012.
14. Centers for Medicare & Medicaid Services. Prescription drug coverage-general information. https://www.cms.hhs.gov/PrescriptionDrugCovGenIn/. Accessed June 26, 2012.
15. RayWA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920.
16. Gage BF,Waterman AD, ShannonW, Boechler M, RichMW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-2870.
17. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest. 2010;138(5):1093-1100.
18. Rosenbaum PR. Model-based direct adjustment. J AmStat Assoc. 1987;82:387-394.
19. Harder VS, Stuart EA, Anthony JC. Propensity score techniques and the assessment of measured covariate balance to test causal associations in psychological research. Psychol Methods. 2010;15 (3):234-249.
20. Xu S, Ross C, Raebel MA, Shetterly S, Blanchette C, Smith D. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health. 2010;13(2):273-277.
21. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550-560.
22. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011; 46(3):399-424.
23. Mamdani M, Sykora K, Li P, et al. Reader's guide to critical appraisal of cohort studies: 2. assessing potential for confounding. BMJ. 2005;330(7497): 960-962.
24. Morgan SL, Todd JJ. A diagnostic routine for the detection of consequential heterogeneity of causal effects. Sociol Methodol. 2008;38:231-281.
25. Tirschwell DL, LongstrethWT Jr. Validating administrative data in stroke research. Stroke. 2002;33(10):2465-2470.
26. Roumie CL, Mitchel E, Gideon PS, Varas-Lorenzo C, Castellsague J, Griffin MR. Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data. Pharmacoepidemiol Drug Saf. 2008;17(1):20-26.
27. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using International Classification of Diseases, Revisions 9 and 10. Stroke. 2005;36 (8):1776-1781.
28. Cunningham A, Stein CM, Chung CP, Daugherty JR, SmalleyWE, RayWA. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20(6):560-566.
29. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115 (21):2689-2696.
30. Wahl PM, Rodgers K, Schneeweiss S, et al. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf. 2010;19(6):596-603.
31. Petersen LA,Wright S, Normand SL, Daley J. Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database. J Gen Intern Med. 1999;14(9):555-558.
32. Levy AR, Tamblyn RM, Fitchett D, McLeod PJ, Hanley JA. Coding accuracy of hospital discharge data for elderly survivors ofmyocardial infarction. Can J Cardiol. 1999;15(11):1277-1282.
33. Austin PC, Daly PA, Tu JV. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J. 2002;144(2): 290-296.
34. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acutemyocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004;148(1):99-104.
35. Choma NN, Griffin MR, Huang RL, et al. An algorithm to identify incidentmyocardial infarction using Medicaid data. Pharmacoepidemiol Drug Saf. 2009;18(11):1064-1071.
36. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
37. Hill ME, Rosenwaike I. The Social Security Administration's Death Master File: The completeness of death reporting at older ages. Soc Secur Bull. 2001-2002;64(1):45-51.
38. Graham DJ, Reichman ME,WerneckeM, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157-164.
39. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ; The Euro Heart Survey on Atrial Fibrillation. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest. 2010; 137(2):263-272.
40. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
41. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral anticoagulant use.AmJ Med. 2015;128(12):1300-5.e2.
42. SouthworthMR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368(14):1272-1274.
43. Gorst-Rasmussen A, Lip GYH, Bjerregaard Larsen T. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiol Drug Saf. 2016.
44. Cannon CP, Kohli P. Danger ahead: watch out for indirect comparisons! J AmColl Cardiol. 2012;60 (8):747-748.
45. Buxton IO, Benet LZ. Pharmacokinetics: The dynamics of drug absorption, distribution, metabolism, and elimination. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 12th ed. New York, NY:McGraw-Hill; 2011. http://accessmedicine.mhmedical.com/content.aspx ?bookid=374&Sectionid=41266207. Accessed November 2, 2015.
46. Chang HY, Zhou M, TangW, Alexander GC, Singh S. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ. 2015;350:h1585.
47. Hernandez I, Baik SH, Piñera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Internal Medicine. 2015;175(1):18-24.
48. Wang SV, Franklin JM, Glynn RJ, Schneeweiss S, EddingsW, Gagne JJ. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. BMJ. 2016;353:i2607.
49. Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015;350:h1857.